- Home
- BOLT vs DRCT Comparison
BOLT vs DRCT Comparison
Compare BOLT & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOLT | DRCT |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.9M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BOLT | DRCT |
|---|---|---|
| Price | $5.81 | $0.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $34.00 | $6.00 |
| AVG Volume (30 Days) | 31.3K | ★ 25.0M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,195,000.00 | ★ $35,369,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.41 | $0.05 |
| 52 Week High | $12.60 | $2.61 |
Technical Indicators
Market Signals| Indicator | BOLT | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 26.99 |
| Support Level | $5.50 | $0.05 |
| Resistance Level | $5.71 | $0.08 |
| Average True Range (ATR) | 0.33 | 0.01 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 84.34 | 21.29 |
Price Performance
Historical ComparisonAbout BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.